Literature DB >> 30012441

Comparative efficacy of antibiotics in treating experimental Clostridium septicum infection.

Michael John Aldape1, Clifford Roland Bayer2, Savannah Nicole Rice2, Amy Evelyn Bryant3, Dennis Leroy Stevens3.   

Abstract

Clostridium septicum is a highly pathogenic microbe that causes gas gangrene in humans, and is the principal cause of spontaneous gas gangrene in patients with gastrointestinal maladies, including adenocarcinoma of the colon. Despite modern approaches to manage C. septicum infection, morbidity and mortality remain high (>60%). At present, no objective in-vivo data exist supporting the current antibiotic treatment recommendations for C. septicum infection. Utilizing an established murine model of clostridial myonecrosis, this study investigated the efficacy of standard antibiotics for anaerobic Gram-positive soft tissue infections (penicillin, clindamycin, tetracycline and vancomycin) in treating C. septicum gas gangrene. Following intramuscular challenge with 1 × 106 colony-forming units of C. septicum, antibiotics were administered by intraperitoneal injection every 4 h for a total of four doses. At 30 h, all animals in all treatment groups survived the C. septicum challenge, compared with no survivors in the untreated controls (100% mortality by 10 h). However, by 60 h, mice treated with vancomycin exhibited 40% mortality, with no mortality observed in any other antibiotic treatment group. Microbroth dilution minimum inhibitory concentration analyses for three strains of C. septicum also demonstrated high susceptibility to penicillin, clindamycin and tetracycline, but considerably lower susceptibility to vancomycin. This study suggests that penicillin, clindamycin and tetracycline are suitable alternatives for the treatment of C. septicum infection in humans.
Copyright © 2018 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.

Entities:  

Keywords:  Antibiotic treatment; Clostridium septicum; In-vivo efficacy

Mesh:

Substances:

Year:  2018        PMID: 30012441      PMCID: PMC6467573          DOI: 10.1016/j.ijantimicag.2018.07.009

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  7 in total

1.  Rapidly progressive and fatal distant spontaneous gas gangrene due to Clostridium septicum after biopsy of malignant cecal mass.

Authors:  Geetha Sivasubramanian
Journal:  IDCases       Date:  2021-04-22

2.  Distant myonecrosis by atraumatic Clostridium septicum infection in a patient with metastatic breast cancer.

Authors:  Kelsey M Gray; Pablo L Padilla; Blake Sparks; Peter Dziewulski
Journal:  IDCases       Date:  2020-05-05

Review 3.  Vaccine Production to Protect Animals Against Pathogenic Clostridia.

Authors:  Nicolas E Zaragoza; Camila A Orellana; Glenn A Moonen; George Moutafis; Esteban Marcellin
Journal:  Toxins (Basel)       Date:  2019-09-11       Impact factor: 4.546

4.  Vertebral augmentation-related Clostridium septicum osteomyelitis.

Authors:  Nicholas Pavlatos; Matthew Kurian; Omar Khan; Allen Guehl; Feras Deek; Azim Shaikh; Mubin I Syed
Journal:  Radiol Case Rep       Date:  2022-08-05

5.  Clostridium myonecrosis - a rare and underdiagnosed condition in the elderly: a case with severe skipping lesions and an overview of treatment guidelines.

Authors:  Ellen Van Asbroeck; Ourania Vasileiadou; Sylvie De Laere; Eddy Van Hedent; Katleen Devue
Journal:  Int J Emerg Med       Date:  2022-10-05

6.  Clostridial Gas Gangrene - A Rare but Deadly Infection: Case series and Comparison to Other Necrotizing Soft Tissue Infections.

Authors:  Maximilian Leiblein; Nils Wagner; Elisabeth H Adam; Johannes Frank; Ingo Marzi; Christoph Nau
Journal:  Orthop Surg       Date:  2020-10-04       Impact factor: 2.071

7.  First Comparative Analysis of Clostridium septicum Genomes Provides Insights Into the Taxonomy, Species Genetic Diversity, and Virulence Related to Gas Gangrene.

Authors:  Prasad Thomas; Mostafa Y Abdel-Glil; Anbazhagan Subbaiyan; Anne Busch; Inga Eichhorn; Lothar H Wieler; Heinrich Neubauer; Mathias Pletz; Christian Seyboldt
Journal:  Front Microbiol       Date:  2021-12-09       Impact factor: 5.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.